{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:22:32Z","timestamp":1770070952434,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.<\/jats:p>","DOI":"10.3389\/fmed.2024.1451264","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:00:44Z","timestamp":1724907644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft"],"prefix":"10.3389","volume":"11","author":[{"given":"Louis","family":"Stavart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Halfon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natacha","family":"Dewarrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Rotman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dela","family":"Golshayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia: prognostic significance","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/1097-0142(19870815)60:4<827::AID-CNCR2820600419>3.0.CO;2-A","article-title":"An autopsy study of 1206 acute and chronic leukemias (1958 to 1982)","volume":"60","author":"Barcos","year":"1987","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00432526","article-title":"Pathoanatomical features of the kidney in myelomonocytic and chronic lymphocytic leukemia","volume":"368","author":"Schwarze","year":"1975","journal-title":"Virchows Archiv A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0046-8177(81)80023-8","article-title":"The effects of leukemic infiltrates in various organs in chronic lymphocytic leukemia","volume":"12","author":"Schwartz","year":"1981","journal-title":"Hum Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1034\/j.1600-0609.2001.5790493.x","article-title":"Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients","volume":"67","author":"Da'as","year":"2001","journal-title":"Eur J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0119156","DOI":"10.1371\/journal.pone.0119156","article-title":"The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia \/ small lymphocytic lymphoma: a 25-year multicenter experience","volume":"10","author":"Poitou-Verkinder","year":"2015","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/archinte.1978.03630320075026","article-title":"Long-term dialysis and renal transplantation in lymphatic leukemia","volume":"138","author":"Davin","year":"1978","journal-title":"Arch Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/j.1600-6143.2008.02383.x","article-title":"Chronic lymphocytic leukemia: a hazardous condition before kidney transplantation","volume":"8","author":"D'Ythurbide","year":"2008","journal-title":"Am J Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1600-6143.2011.03439.x","article-title":"Chronic lymphocytic leukemia in kidney recipients","volume":"11","author":"d\u2019Ythurbide","year":"2011","journal-title":"Am J Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.13759","article-title":"Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia","volume":"174","author":"Strati","year":"2016","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.kint.2020.07.037","article-title":"Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants","volume":"99","author":"Nasr","year":"2021","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/ndt\/gfp444","article-title":"Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy","volume":"24","author":"Dierickx","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/01.TP.0000047309.31708.CD","article-title":"Simultaneous kidney-pancreas transplantation in a patient with small lymphocytic lymphoma","volume":"75","author":"Romero","year":"2003","journal-title":"Transplantation"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e13338","DOI":"10.1111\/ctr.13338","article-title":"Immunophenotypic profile and clinical outcome of monoclonal B-cell lymphocytosis in kidney transplantation","volume":"32","author":"Alfano","year":"2018","journal-title":"Clin Transpl"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e242889","DOI":"10.1136\/bcr-2021-242889","article-title":"Monoclonal B lymphocytosis in a kidney transplant recipient","volume":"14","author":"Plessi","year":"2021","journal-title":"BMJ Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/TP.0b013e3182997d11","article-title":"Lymphocytic lymphoma\/chronic lymphocytic leukemia in a solid-organ donor: an unestablished risk in elderly donors","volume":"96","author":"Collantes","year":"2013","journal-title":"Transplantation"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1016\/j.transproceed.2018.04.016","article-title":"Living kidney donor with small lymphocytic lymphoma at the time of donation: a case report","volume":"50","author":"Tatarano","year":"2018","journal-title":"Transplant Proc"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/ki.1992.270","article-title":"Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas","volume":"42","author":"Moulin","year":"1992","journal-title":"Kidney Int"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102552","article-title":"Chemokine CXCL13 as a new systemic biomarker for B-cell involvement in acute T cell-mediated kidney allograft rejection","volume":"20","author":"Schiffer","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/TP.0000000000001588","article-title":"Crosstalk between T and B cells in the germinal center after transplantation","volume":"101","author":"Kwun","year":"2017","journal-title":"Transplantation"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/cncr.34787","article-title":"Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity","volume":"129","author":"Gordon","year":"2023","journal-title":"Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOT.0000000000001034","article-title":"Delayed graft function: current status and future directions","volume":"28","author":"Swanson","year":"2023","journal-title":"Curr Opin Organ Transplant"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1451264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:00:47Z","timestamp":1724907647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1451264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":33,"alternative-id":["10.3389\/fmed.2024.1451264"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1451264","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"article-number":"1451264"}}